nach oben

Current Diabetes Reports

Erschienen in:

01.12.2013 | Genetics (TM Frayling, Section Editor)

Bridging the Gap Between Genetic Associations and Molecular Mechanisms for Type 2 Diabetes

verfasst von: Hui Jin Ng, Anna L. Gloyn

Erschienen in: Current Diabetes Reports | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Type 2 diabetes is a global pandemic for which there is currently no disease-modifying treatment. New and targeted therapeutics are greatly needed, but progress in identifying novel targets for therapeutic intervention is severely hampered by poor understanding of disease pathogenesis. Over the past 6 years, the success of genome-wide association studies has led to an unprecedented increase in the number of loci robustly associating with type 2 diabetes risk. Each of these signals offers the opportunity to uncover biological insights into disease pathogenesis, which, if harnessed effectively, hold the promise to deliver new pathways for therapeutic intervention, strategies for patient stratification, and potentially, biomarkers for identifying those at greatest risk of developing diabetes. We review the progress that has been made and the approaches being adopted and discuss the inherent challenges in moving from association signals, which largely map to poorly annotated sequence, to transcripts, mechanisms, and disease biology.

Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44:981–90.PubMedCrossRef

Rosenbloom KR, Sloan CA, Malladi VS, et al. ENCODE data in the UCSC genome browser: year 5 update. Nucleic Acids Res. 2013;41:D56–63.PubMedCrossRef

Willer CJ, Speliotes EK, Loos RJF, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet. 2009;41:25–34.PubMedCrossRef

Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105–16.PubMedCrossRef

Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42:579–89.PubMedCrossRef

Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010;42:142–8.PubMedCrossRef

Strawbridge RJ, Dupuis J, Prokopenko I, et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes. 2011;60:2624–34.PubMedCrossRef

• Ingelsson E, Langenberg C, Hivert MF, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes. 2010;59:1266–75. An investigation of the effects of genetic variants associated with T2D risk on measures of insulin processing, secretion, and sensitivity.PubMedCrossRef

Orho-Melander M, Melander O, Guiducci C, et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes. 2008;57:3112–21.PubMedCrossRef

10.

Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet. 2009;18:4081–8.PubMedCrossRef

11.

• Rees MG, Wincovitch S, Schultz J, et al. Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia. 2012;55:114–22. A functional study of the common coding variant P446L in GKRP that revealed the potential cellular mechanism by which the variant influences T2D risk.PubMedCrossRef

12.

Rees MG, Gloyn AL. Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour? Br J Pharmacol. 2013;168:335–8.PubMedCrossRef

13.

Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445:881–5.PubMedCrossRef

14.

Pound LD, Sarkar SA, Benninger RK, et al. Deletion of the mouse Slc30a8 gene encoding zinc transporter-8 results in impaired insulin secretion. Biochem J. 2009;421:371–6.PubMedCrossRef

15.

Lemaire K, Ravier MA, Schraenen A, et al. Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. Proc Natl Acad Sci U S A. 2009;106:14872–7.PubMedCrossRef

16.

Nicolson TJ, Bellomo EA, Wijesekara N, et al. Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. Diabetes. 2009;58:2070–83.PubMedCrossRef

17.

Wijesekara N, Dai FF, Hardy AB, et al. Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion. Diabetologia. 2010;53:1656–68.PubMedCrossRef

18.

Pound LD, Sarkar SA, Ustione A, et al. The physiological effects of deleting the mouse Slc30a8 gene encoding zinc transporter-8 are influenced by gender and genetic background. Plos One. 2012;7:e40972.PubMedCrossRef

19.

Sakura H, Wat N, Horton V, et al. Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in white Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia. 1996;39:1233–6.PubMedCrossRef

20.

Schwanstecher C, Meyer U, Schwanstecher M. Kir6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic β-cell ATP-Sensitive K⁺ channels. Diabetes. 2002;51:875–9.PubMedCrossRef

21.

Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell K-ATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52:568–72.PubMedCrossRef

22.

Riedel MJ, Boora P, Steckley D, et al. Kir6.2 polymorphisms sensitize beta-cell ATP-sensitive potassium channels to activation by acyl CoAs: a possible cellular mechanism for increased susceptibility to type 2 diabetes? Diabetes. 2003;52:2630–5.PubMedCrossRef

23.

Florez JC, Burtt N, de Bakker PI, et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes. 2004;53:1360–8.PubMedCrossRef

24.

Hamming KS, Soliman D, Matemisz LC, et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes. 2009;58:2419–24.PubMedCrossRef

25.

Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747–53.PubMedCrossRef

26.

•• Rees MG, Ng D, Ruppert S, et al. Correlation of rare coding variants in the gene encoding human glucokinase regulatory protein with phenotypic, cellular, and kinetic outcomes. J Clin Invest. 2012;122:205–17. A comprehensive functional analysis of common and rare nonsynonymous variants in GCKR identified through targeted exon sequencing.PubMedCrossRef

27.

•• Bonnefond A, Clement N, Fawcett K, et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet. 2012;44:297–301. A functional analysis of common and rare nonsynonymous variants in MTNR1B identified through large-scale exon resequencing, which reaffirmed a functional link between the gene and T2D risk.PubMedCrossRef

28.

Kong A, Steinthorsdottir V, Masson G, et al. Parental origin of sequence variants associated with complex diseases. Nature. 2009;462:868–74.PubMedCrossRef

29.

• Small KS, Hedman AK, Grundberg E, et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet. 2011;43:561–4. An association study that showed that an eQTL of KLF14 trans-regulates adipose gene expression and, hence, established links between expression levels of several genetic loci and metabolic phenotypes.PubMedCrossRef

30.

Rung J, Cauchi S, Albrechtsen A, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009;41:1110–5.PubMedCrossRef

31.

Kilpelainen TO, Zillikens MC, Stancakova A, et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet. 2011;43:753–60.PubMedCrossRef

32.

•• Gaulton KJ, Nammo T, Pasquali L, et al. A map of open chromatin in human pancreatic islets. Nat Genet. 2010;42:255–9. A landmark study that provided a profile of open chromatin sites in human islets that can be used to identify regulatory roles of variants, such as that of TCF7L2, that underlie disease susceptibility.PubMedCrossRef

33.

Fogarty MP, Panhuis TM, Vadlamudi S, et al. Allele-specific transcriptional activity at type 2 diabetes-associated single nucleotide polymorphisms in regions of pancreatic islet open chromatin at the JAZF1 locus. Diabetes. 2013;62:1756–62.PubMedCrossRef

34.

•• Stitzel ML, Sethupathy P, Pearson DS, et al. Global epigenomic analysis of primary human pancreatic islets provides insights into type 2 diabetes susceptibility loci. Cell Metab. 2010;12:443–55. A genome-wide analysis that generated a profile of the epigenome of human islets to enhance the understanding of gene regulation in islets and the role of noncoding variants in disease susceptibility.PubMedCrossRef

35.

•• Moran I, Akerman I, van de Bunt M, et al. Human beta cell transcriptome analysis uncovers IncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metab. 2012;16:435–48. A study describing a comprehensive transcriptome map of human islets and beta cells that first revealed the role of lncRNAs in beta cell physiology and disease.PubMedCrossRef

36.

Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.PubMedCrossRef

37.

Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–30.PubMedCrossRef

38.

Zhu H, Shyh-Chang N, Segre AV, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147:81–94.PubMedCrossRef

39.

• van de Bunt M, Gaulton KJ, Parts L, et al. The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis. PLoS One. 2013;8:e55272. A study that used small RNA sequencing to generate an miRNA profile in human islets and beta cells to evaluate the role of islet-expressed miRNAs and their targets in diabetes pathogenesis.PubMedCrossRef

40.

Travers ME, Mackay DJG, Nitert MD, et al. Insights into the molecular mechanism for 2 diabetes susceptibility at the KCNQ1 locus from temporal changes in imprinting status in human islets. Diabetes. 2013;62:987–92.PubMedCrossRef

41.

Dayeh TA, Olsson AH, Volkov P, et al. Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets. Diabetologia. 2013;56:1036–46.PubMedCrossRef

42.

Unoki H, Takahashi A, Kawaguchi T, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet. 2008;40:1098–102.PubMedCrossRef

43.

Jonsson A, Isomaa B, Tuomi T, et al. A variant in the KCNQ1 gene predicts future type 2 diabetes and mediates impaired insulin secretion. Diabetes. 2009;58:2409–13.PubMedCrossRef

44.

Gutierrez-Arcelus M, Lappalainen T, Montgomery SB, et al. Passive and active DNA methylation and the interplay with genetic variation in gene regulation. Elife. 2013;2:e00523.PubMedCrossRef

45.

Skarnes WC, Rosen B, West AP, et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature. 2011;474:337–42.PubMedCrossRef

46.

McMurray F, Moir L, Cox RD. From mice to humans. Curr Diab Rep. 2012;12:651–8.PubMedCrossRef

47.

Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet. 2007;39:770–5.PubMedCrossRef

48.

Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316:1336–41.PubMedCrossRef

49.

Groenewoud MJ, Dekker JM, Fritsche A, et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia. 2008;51:1659–63.PubMedCrossRef

50.

•• Wei FY, Suzuki T, Watanabe S, et al. Deficit of tRNA(Lys) modification by Cdkal1 causes the development of type 2 diabetes in mice. J Clin Invest. 2011;121:3598–608. An elegant study of Cdkal1 in beta-cell-specific knockout mice that uncovered both the molecular function of Cdkal1 in protein translation and the mechanism by which Cdkal1 deficiency may lead to development of T2D.PubMedCrossRef

51.

McCarthy MI, Rorsman P, Gloyn AL. TCF7L2 and diabetes: a tale of two tissues, and of two species. Cell Metab. 2013;17:157–9.PubMedCrossRef

52.

Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117:2155–63.PubMedCrossRef

53.

Le Bacquer O, Kerr-Conte J, Gargani S, et al. TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals. Diabetologia. 2012;55:2677–81.PubMedCrossRef

54.

• Xavier GD, Mondragon A, Sun G, et al. Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice. Diabetologia. 2012;55:2667–76. A study characterising pancreas-specific Tcf7l2 knockout mice that showed that selective loss of Tcf7l2 results in an islet phenotype through the impairment of insulin secretion and glucose homeostasis.CrossRef

55.

•• Boj SF, van Es JH, Huch M, et al. Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell. 2012;151:1595–607. A comprehensive study of global and tissue-specific inducible mouse models that, surprisingly, showed that depletion of Tcf7l2 primarily disrupts liver metabolism, providing new insight into the role of TCF4 in diabetes development.PubMedCrossRef

56.

Klupa T, Skupien J, Malecki MT. Monogenic models: what have the single gene disorders taught us? Curr Diab Rep. 2012;12:659–66.PubMedCrossRef

57.

Pal A, Barber TM, van de Bunt M, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med. 2012;367:1002–11.PubMedCrossRef

58.

Scott RA, Lagou V, Welch RP, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44:991–1005.PubMedCrossRef

59.

•• Nica AC, Ongen H, Irminger JC et al. Cell-type, allelic and genetic signatures in the human pancreatic beta cell transcriptome. Genome Res. 2013; In press. The first characterization of the human beta cell transcriptome based on deep RNA sequencing that will shed light on cell-specific expression signatures and aid the study of diabetes-associated loci involved in beta cell gene expression.

60.

•• Ravassard P, Hazhouz Y, Pechberty S, et al. A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion. J Clin Invest. 2011;121:3589–97. A study describing the generation of a stable and functional human beta cell line that can be used as a cellular model to probe human beta cell physiology and as a preclinical model for developing therapeutics for diabetes.PubMedCrossRef

61.

Bar-Nur O, Russ HA, Efrat S, et al. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 2011;9:17–23.PubMedCrossRef

62.

Bellin M, Marchetto MC, Gage FH, et al. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol. 2012;13:713–26.PubMedCrossRef

63.

Christian M, Cermak T, Doyle EL, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics. 2010;186:757–61.PubMedCrossRef

64.

•• Joung JK, Sander JD. INNOVATION TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013;14:49–55. A review article describing the use of TALENs for targeted genome alteration in a wide range of cell types and organisms, as well as highlighting the exciting prospects that will emerge from the development of TALE technology.PubMedCrossRef

65.

•• Mali P, Yang LH, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823–6. A report of a novel RNA-guided genome-editing tool engineered from the bacterial CRISPR system that promises efficient gene targeting in mammalian cells in a robust and multiplexable manner.PubMedCrossRef

Titel: Bridging the Gap Between Genetic Associations and Molecular Mechanisms for Type 2 Diabetes
verfasst von: Hui Jin Ng
Anna L. Gloyn
Publikationsdatum: 01.12.2013
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 6/2013
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-013-0429-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Impact of Behavioral Interventions in the Management of Adults with Type 2 Diabetes Mellitus

Eating Disorders and Disordered Eating in Type 1 Diabetes: Prevalence, Screening, and Treatment Options

Moving on from GWAS: Functional Studies on the G6PC2 Gene Implicated in the Regulation of Fasting Blood Glucose

Physical Disability in the Elderly with Diabetes: Epidemiology and Mechanisms

Epidemiology of Diabetes and Diabetes Complications in the Elderly: An Emerging Public Health Burden